Abstract
A novel series of CCR5 antagonists has been identified, utilizing leads from high-throughput screening which were further modified based on insights from competitor molecules. Lead optimization was pursued by balancing opposing trends of metabolic stability and potency. Selective and potent analogs with good pharmacokinetic properties were successfully developed.
MeSH terms
-
Animals
-
CCR5 Receptor Antagonists*
-
Caco-2 Cells
-
Dogs
-
Haplorhini
-
Humans
-
Piperidines / chemistry*
-
Piperidines / pharmacokinetics
-
Piperidines / pharmacology*
-
Rats
-
Receptors, CCR5 / metabolism*
-
Spiro Compounds / chemistry
-
Spiro Compounds / pharmacokinetics
-
Spiro Compounds / pharmacology
-
Structure-Activity Relationship
Substances
-
CCR5 Receptor Antagonists
-
Piperidines
-
Receptors, CCR5
-
Spiro Compounds